Rational Use of Danofloxacin for Treatment of <i>Mycoplasma gallisepticum</i> in Chickens Based on the Clinical Breakpoint and Lung Microbiota Shift
The study was to explore the rational use of danofloxacin against <i>Mycoplasma gallisepticum</i> (<i>MG</i>) based on its clinical breakpoint (CBP) and the effect on lung microbiota. The CBP was established according to epidemiological cutoff value (ECV/CO<sub>WT</s...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/11/3/403 |
| _version_ | 1827650177428619264 |
|---|---|
| author | Shuge Wang Anxiong Huang Yufeng Gu Jun Li Lingli Huang Xu Wang Yanfei Tao Zhenli Liu Congming Wu Zonghui Yuan Haihong Hao |
| author_facet | Shuge Wang Anxiong Huang Yufeng Gu Jun Li Lingli Huang Xu Wang Yanfei Tao Zhenli Liu Congming Wu Zonghui Yuan Haihong Hao |
| author_sort | Shuge Wang |
| collection | DOAJ |
| description | The study was to explore the rational use of danofloxacin against <i>Mycoplasma gallisepticum</i> (<i>MG</i>) based on its clinical breakpoint (CBP) and the effect on lung microbiota. The CBP was established according to epidemiological cutoff value (ECV/CO<sub>WT</sub>), pharmacokinetic–pharmacodynamic (PK–PD) cutoff value (CO<sub>PD</sub>) and clinical cutoff value (CO<sub>CL</sub>). The ECV was determined by the micro-broth dilution method and analyzed by ECOFFinder software. The CO<sub>PD</sub> was determined according to PK–PD modeling of danofloxacin in infected lung tissue with Monte Carlo analysis. The CO<sub>CL</sub> was performed based on the relationship between the minimum inhibitory concentration (MIC) and the possibility of cure (POC) from clinical trials. The CBP in infected lung tissue was 1 μg/mL according to CLSI M37-A3 decision tree. The 16S ribosomal RNA (rRNA) sequencing results showed that the lung microbiota, especially the phyla <i>Fi</i><i>rmicutes</i> and <i>Proteobacteria</i> had changed significantly along with the process of cure regimen (the 24 h dosing interval of 16.60 mg/kg b.w for three consecutive days). Our study suggested that the rational use of danofloxacin for the treatment of <i>MG</i> infections should consider the MIC and effect of antibiotics on the respiratory microbiota. |
| first_indexed | 2024-03-09T20:11:43Z |
| format | Article |
| id | doaj.art-80b2df0098c44529a5acf6b7952f7430 |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-03-09T20:11:43Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-80b2df0098c44529a5acf6b7952f74302023-11-24T00:12:03ZengMDPI AGAntibiotics2079-63822022-03-0111340310.3390/antibiotics11030403Rational Use of Danofloxacin for Treatment of <i>Mycoplasma gallisepticum</i> in Chickens Based on the Clinical Breakpoint and Lung Microbiota ShiftShuge Wang0Anxiong Huang1Yufeng Gu2Jun Li3Lingli Huang4Xu Wang5Yanfei Tao6Zhenli Liu7Congming Wu8Zonghui Yuan9Haihong Hao10National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Wuhan 430070, ChinaNational Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Wuhan 430070, ChinaNational Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Wuhan 430070, ChinaInstitute of Food Safety and Nutrition, Jiangsu Academy of Agricultural Sciences, Nanjing 210014, ChinaNational Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Wuhan 430070, ChinaNational Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Wuhan 430070, ChinaNational Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Wuhan 430070, ChinaNational Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Wuhan 430070, ChinaNational Center for Veterinary Drug Safety Evaluation, College of Veterinary Medicine, China Agricultural University, Beijing 100193, ChinaNational Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Wuhan 430070, ChinaNational Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Wuhan 430070, ChinaThe study was to explore the rational use of danofloxacin against <i>Mycoplasma gallisepticum</i> (<i>MG</i>) based on its clinical breakpoint (CBP) and the effect on lung microbiota. The CBP was established according to epidemiological cutoff value (ECV/CO<sub>WT</sub>), pharmacokinetic–pharmacodynamic (PK–PD) cutoff value (CO<sub>PD</sub>) and clinical cutoff value (CO<sub>CL</sub>). The ECV was determined by the micro-broth dilution method and analyzed by ECOFFinder software. The CO<sub>PD</sub> was determined according to PK–PD modeling of danofloxacin in infected lung tissue with Monte Carlo analysis. The CO<sub>CL</sub> was performed based on the relationship between the minimum inhibitory concentration (MIC) and the possibility of cure (POC) from clinical trials. The CBP in infected lung tissue was 1 μg/mL according to CLSI M37-A3 decision tree. The 16S ribosomal RNA (rRNA) sequencing results showed that the lung microbiota, especially the phyla <i>Fi</i><i>rmicutes</i> and <i>Proteobacteria</i> had changed significantly along with the process of cure regimen (the 24 h dosing interval of 16.60 mg/kg b.w for three consecutive days). Our study suggested that the rational use of danofloxacin for the treatment of <i>MG</i> infections should consider the MIC and effect of antibiotics on the respiratory microbiota.https://www.mdpi.com/2079-6382/11/3/403danofloxacin<i>Mycoplasma gallisepticum</i>epidemiological cutoff valuesPK–PD cutoff valuesclinical cutoff valuesclinical breakpoint |
| spellingShingle | Shuge Wang Anxiong Huang Yufeng Gu Jun Li Lingli Huang Xu Wang Yanfei Tao Zhenli Liu Congming Wu Zonghui Yuan Haihong Hao Rational Use of Danofloxacin for Treatment of <i>Mycoplasma gallisepticum</i> in Chickens Based on the Clinical Breakpoint and Lung Microbiota Shift Antibiotics danofloxacin <i>Mycoplasma gallisepticum</i> epidemiological cutoff values PK–PD cutoff values clinical cutoff values clinical breakpoint |
| title | Rational Use of Danofloxacin for Treatment of <i>Mycoplasma gallisepticum</i> in Chickens Based on the Clinical Breakpoint and Lung Microbiota Shift |
| title_full | Rational Use of Danofloxacin for Treatment of <i>Mycoplasma gallisepticum</i> in Chickens Based on the Clinical Breakpoint and Lung Microbiota Shift |
| title_fullStr | Rational Use of Danofloxacin for Treatment of <i>Mycoplasma gallisepticum</i> in Chickens Based on the Clinical Breakpoint and Lung Microbiota Shift |
| title_full_unstemmed | Rational Use of Danofloxacin for Treatment of <i>Mycoplasma gallisepticum</i> in Chickens Based on the Clinical Breakpoint and Lung Microbiota Shift |
| title_short | Rational Use of Danofloxacin for Treatment of <i>Mycoplasma gallisepticum</i> in Chickens Based on the Clinical Breakpoint and Lung Microbiota Shift |
| title_sort | rational use of danofloxacin for treatment of i mycoplasma gallisepticum i in chickens based on the clinical breakpoint and lung microbiota shift |
| topic | danofloxacin <i>Mycoplasma gallisepticum</i> epidemiological cutoff values PK–PD cutoff values clinical cutoff values clinical breakpoint |
| url | https://www.mdpi.com/2079-6382/11/3/403 |
| work_keys_str_mv | AT shugewang rationaluseofdanofloxacinfortreatmentofimycoplasmagallisepticumiinchickensbasedontheclinicalbreakpointandlungmicrobiotashift AT anxionghuang rationaluseofdanofloxacinfortreatmentofimycoplasmagallisepticumiinchickensbasedontheclinicalbreakpointandlungmicrobiotashift AT yufenggu rationaluseofdanofloxacinfortreatmentofimycoplasmagallisepticumiinchickensbasedontheclinicalbreakpointandlungmicrobiotashift AT junli rationaluseofdanofloxacinfortreatmentofimycoplasmagallisepticumiinchickensbasedontheclinicalbreakpointandlungmicrobiotashift AT linglihuang rationaluseofdanofloxacinfortreatmentofimycoplasmagallisepticumiinchickensbasedontheclinicalbreakpointandlungmicrobiotashift AT xuwang rationaluseofdanofloxacinfortreatmentofimycoplasmagallisepticumiinchickensbasedontheclinicalbreakpointandlungmicrobiotashift AT yanfeitao rationaluseofdanofloxacinfortreatmentofimycoplasmagallisepticumiinchickensbasedontheclinicalbreakpointandlungmicrobiotashift AT zhenliliu rationaluseofdanofloxacinfortreatmentofimycoplasmagallisepticumiinchickensbasedontheclinicalbreakpointandlungmicrobiotashift AT congmingwu rationaluseofdanofloxacinfortreatmentofimycoplasmagallisepticumiinchickensbasedontheclinicalbreakpointandlungmicrobiotashift AT zonghuiyuan rationaluseofdanofloxacinfortreatmentofimycoplasmagallisepticumiinchickensbasedontheclinicalbreakpointandlungmicrobiotashift AT haihonghao rationaluseofdanofloxacinfortreatmentofimycoplasmagallisepticumiinchickensbasedontheclinicalbreakpointandlungmicrobiotashift |